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Abstract
Background: Multimeric naphthoquinones are redox-active compounds that exhibit antineoplastic, antiprotozoal,
and antiviral activities. Due to their multimodal effect on perturbation of cellular oxidative state, these compounds
hold great potential as therapeutic agents against highly proliferative neoplastic cells. In our previous work, we
developed a series of novel dimeric naphthoquinones and showed that they were selectively cytotoxic to human
acute myeloid leukemia (AML), breast and prostate cancer cell lines. We subsequently identified the oxidoreductase
NAD(P)H dehydrogenase, quinone 1 (NQO1) as the major target of dimeric naphthoquinones and proposed a
mechanism of action that entailed induction of a futile redox cycling.
Results: Here, for the first time, we describe a direct physical interaction between the bromohydroxy dimeric
naphthoquinone E6a and NQO1. Moreover, our studies reveal an extensive binding interface between E6a and the
isoalloxazine ring of the flavin adenine dinucleotide (FAD) cofactor of NQO1 in addition to interactions with protein
side chains in the active site. We also present biochemical evidence that dimeric naphthoquinones affect the redox
state of the FAD cofactor of NQO1. Comparison of the mode of binding of E6a with those of other chemotherapeutics
reveals unique characteristics of the interaction that can be leveraged in future drug optimization efforts.
Conclusion: The first structure of a dimeric naphthoquinone-NQO1 complex was reported, which can be used for
design and synthesis of more potent next generation dimeric naphthoquinones to target NQO1 with higher affinity
and specificity.
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Background
Multimeric naphthoquinones are reduction/oxidation
(redox)-active compounds that possess a wide array of
therapeutic activities. In particular, these compounds
have exhibited well tolerated antibacterial, antifungal,
antiviral, and antithrombotic activities [1]. One of the
most notable members of this class of compounds is
conocurvone, a naturally-occurring trimeric naphthoqui-
none with a potent anti-HIV activity [2]. Synthetic and
natural naphthoquinones have demonstrated significant
antineoplastic activity against hematologic and solid
malignant cells [3–5]. In an effort to regiospecifically
synthesize conocurvone, we previously developed a
series of novel dimeric naphthoquinones and showed
that they were selectively cytotoxic to human acute mye-
loid leukemia (AML), breast and prostate cancer cell
lines and in particular those cell lines that rely on oxida-
tive phosphorylation [6–8]. To better understand the
mechanism of action of these agents, we performed a
chemical genetic screen in yeast and identified the yeast
oxidoreductase Nde1 as the major target of dimeric
naphthoquinones [6, 9]. The human homologue of Nde1
is NAD(P)H quinone oxidoreductase 1 (E.C. 1.6.99.2,
hereon referred to as NQO1, also known as DT-
diaphorase and NAD(P)H dehydrogenase, quinone 1).
NQO1 is a quinone detoxifying flavoenzyme that cata-
lyzes the two-electron reduction of quinones to hydroqui-
nones. For dimeric naphthoquinones, the resulting
hydroquinone is highly unstable and spontaneously gives
electrons to oxygen and reverts to the oxidized form of
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quinone, producing two moles of superoxide per one mole
of NAD(P)H [10]. The ultimate outcome is a futile redox
cycle in NQO1-overexpressing cells, such as many cancer
cells, which can culminate in formation of substantial
reactive oxygen species (ROS), oxidative damage to DNA
and single- and double-strand DNA breaks. NQO1 exists
as a homodimer with two tightly-associated flavin adenine
dinucleotide (FAD) cofactors that reside at the deepest
point of each active site of two monomers of 274 residues
[11]. The two active sites reside at opposite ends of the
dimer and incorporate residues from each monomer. The
normal biological function of NQO1 is to protect cells
from the mutagenic, cytotoxic, and carcinogenic effects of
natural and synthetic quinones [12]. The obligate two
electron reduction performed by NQO1 averts one-
electron reduction of quinones by other flavoproteins such
as cytochrome P450, which produces highly reactive
radical semiquinone.
The role of NQO1 in cancer varies due to its role in
redox biology. NQO1 exhibits tumor suppressor proper-
ties by modulating the stability of p53 [13, 14] and partici-
pating in suppression of the inflammatory response [15].
Conversely, increased expression of NQO1 can confer a
growth advantage in some cancers such as melanoma,
pancreatic adenocarcinoma, non-small cell lung cancer,
and prostate cancer [16, 17]. The association between the
NQO1 C609T polymorphism and increased risk of AML
and acute lymphoblastic leukemia (ALL) has also been
reported [18, 19]. Exploitation of NQO1 as a target for
cancer therapy typically entails two strategies. In some
cases, inhibition of NQO1 can suppress cancer cell growth
and potentiate chemotherapeutic cytotoxicity [20]. In
other cases, NQO1 can be used to activate particular
quinone-based chemotherapeutics via its redox activity
[21, 22]. For dimeric naphthoquinones, we have proposed
that their unique chemical structures undergo NQO1-
dependent redox cycling that produces an insurmountable
amount of ROS that ultimately lead to mitochondrial
dysfunction, DNA damage and cell death [9].
In the present study, we have determined the crystal
structure of the novel dimeric naphthoquinone, 3-
bromo-3′-hydroxy-2,2′-binaphthalenyl-1,4,1′,4′-tetraone
(E6a [23], Additional file 1: Figure S1) bound to NQO1.
This structure represents the first evidence of a direct
interaction between a dimeric naphthoquinone and
NQO1. Moreover, we present biochemical evidence that
this interaction affects the redox state of the FAD cofac-
tor. Our structure reveals an extensive binding interface
between E6a and the isoalloxazine ring of the FAD
cofactor of NQO1 in addition to interactions with
protein side chains in the active site. This structure can
be used as a starting point to design and synthesize
more potent dimeric naphthoquinones tailored to target
NQO1 with high affinity and specificity.
Results and discussion
Overall quality of crystal structure
Crystals of hNQO1-FAD (holo-hNQO1) belong to space
group P21 and diffract to 2.0 Å resolution. The asym-
metric unit contains two dimers. The crystal structure
shows excellent stereochemistry with 96 % of residues in
the most favored region of Ramachandran plot. Each
physiological dimer [11, 24–27] is made up of two sub-
units that are related by a non-crystallographic two fold
axis. The overall structure of the dimer is almost identical
to that of a previously-determined holo-NQO1 structure
(PDB accession code: 1D4A [26]) with a root-mean-
square deviation (rmsd) of 0.1 Å. We observe unexplained
Fo-Fc density in the active site which does not belong to
any of the possible ingredients of protein purification and/
or crystallization. When we try to model benzoic acid in
this density, it refines to partial occupancy (0.5). The
crystal structure of the hNQO1-FAD-E6a complex was
determined to a resolution of 2.9 Å with excellent stereo-
chemistry (Table 1) as 93 % of the residues reside in the
most favored region of Ramachandran plot. The overall
structure shows interpretable electron density for most of
the polypeptide chain and five bound E6a molecules. The
asymmetric unit of this P212121 crystal form contains
seven physiological dimers. Each physiological dimer is
formed by two subunits related by non-crystallographic
symmetry. Residues 1–273 (of 274 for the full-length
protein) are visible in each monomer. The overall struc-
ture of each of the seven dimers is nearly identical to
holo-hNQO1 except for a few changes in residues at the
active site region interacting with E6a and the isoalloxa-
zine ring of FAD. The Cα superposition of seven dimers
onto those of the holo-hNQO1 (above) and to that of
1D4A resulted in rmsd ranging from 0.26 to 0.27 Å. In
Table 1 Data collection and refinement statistics
hNQO1 Apo hNQO1+E6a
Space Group P21 P212121
Unit Cell (Å) a = 56.93 a = 95.60
b = 107.16 b = 210.77
c = 99.76 c = 228.08
β = 100.68
Resolution (Å) 2.01 2.9
Unique Reflections 72707 102839
Multiplicity (Last shell) 2.7 (2.5) 11.7 (10.4)





Rms Bond/angle 0.01/1.7 0.01/1.1
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this crystal form, a considerable amount of surface area is
buried by the inter-dimer interactions (>1000 Å2 for all
but one pair) with neighboring dimers within the asym-
metric unit as well as those related by crystallographic
symmetry.
Each subunit in the physiological dimer contains a
catalytic domain (1–220) and a C-terminal domain
(221–273). Each dimer of hNQO1 has two active sites
formed at opposite ends of the dimer interface (Fig. 1).
Each catalytic domain has a bound FAD molecule with
its adenine ring interacting mainly with the catalytic do-
main and isoalloxazine ring present at the dimer inter-
face. The flavin of the FAD forms the floor of the
catalytic site while the residues Trp105, Phe106, Gly149,
Gly150, Tyr155, His161 from one subunit contribute to
hydrophobic walls and Tyr126′, Tyr128′ and Phe178′
from the other subunit make up the roof. The noticeable
differences at the active site of holo-hNQO1, when
compared to that of 1D4A, include differences in the
side chain orientations of Phe106, Tyr128′, Phe178′ and
Phe232′ (Additional file 2: Figure S2). There are no
significant changes in the overall structure upon E6a
binding with the exception that the loop containing ac-
tive site residues (main chain of residues 127–130)
moves about 1.2–1.5 Å (measured at Cα of Tyr128′)
towards the active site contributing to the slight shift in
the position of Tyr128′. Residues Phe232 and Gln233
from a loop (230–236) face away from the dimer and
interact with the active site of neighboring dimer
(Additional file 3: Figure S3). As this loop competes for
space with that of the active site loop containing
Tyr128′, only the side chain of either Tyr128′ or
Gln233″ (i.e. not both) are ordered in each active site.
Tyr128′ from subunit K and corresponding Gln233″ are
well-ordered in the active site containing E6a. Hence this
active site was used for the analysis and making figures.
There are no significant changes in the overall structures
of these complexes when compared to the holo form
except for the active site residues Tyr126′ Tyr128′ and
Phe178′ (Fig. 2). FAD binding is identical to that of the
holo form. This is consistent with previously reported
crystal structures, which show that the substrates
NADH, chemotherapeutic quinones and coumarin-
based inhibitors bind at this active site with minor differ-
ences in active site architecture [11, 28–30].
E6a interactions with the NQO1 active site
E6a binds in the active site at the same site as the nico-
tinamide ring of NADH as observed in a previous study
[29]. Five out of 14 active sites show clear density for
most atoms of the dimeric naphthoquinone (Fig. 3a).
The E6a was modelled into the electron density at the
active site by positioning its Br atom in the Fo-Fc map
contoured at 5σ. Two more active sites show clear density
for only one ring, i.e., the brominated naphthoquinone
ring. Partial density is visible for the hydroxyl-containing
naphthoquinone ring. Approximately 116.8 Å2 of surface
area of FAD is buried upon E6a binding. This is almost
two fifths of the surface area buried by protein atoms in
the interaction (299.0 Å2). This indicates that interactions
with FAD contribute substantial favorable energy to the
interaction with E6a. E6a binds with its halogenated
naphthoquinone ring (Ring A) stacking against the isoal-
loxazine ring of FAD with the remainder of the compound
Fig. 1 The biological dimer of hNQO1 with two active sites, one at each end of the dimer interface. One monomer is colored magenta while the
other monomer is colored blue. Two FAD molecules present at each active site are shown orange and an E6a molecule is shown in green. The
inset shows the surface area buried upon FAD-E6a interaction
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Fig. 2 Conformational changes at the active site of holo (orange) and E6a bound (blue) hNQO1
Fig. 3 a 2Fo-Fc electron density for E6a contoured at 1σ. b Interactions of E6a with the active site residues of hNQO1. The residues from one
subunit are represented in blue while the second subunit is shown in magenta. E233 from neighboring dimer is shown in light pink. The hydrogen
bonds are shown in gray and weak electrostatic interactions in pale blue
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interacting with the residues from both subunits of the
dimer. The distance between the isoalloxazine ring and
the brominated ring of E6a is approximately 3.7 Å. In this
position the quinone core of E6a interacts mostly with A
and B rings of the flavin. Most of the interactions of
brominated ring of E6a with FAD are hydrophobic except
for a hydrogen bond between O19 of E6a and hydrogen
attached to N10 of the central ring of the isoalloxazine
moiety and a weak electrostatic interaction of 3.5 Å
between O41 of E6a and O3′ of FAD (Fig. 3b). The bromi-
nated ring of E6a sits in a hydrophobic pocket lined by
Trp105, Phe106, Phe178′, Tyr126′ and Tyr128′. Of these
residues, Tyr128′ participates in a hydrogen bond with
O20 of E6a while Tyr126′engages in a weak electrostatic
interaction (3.5 Å) with O19 of E6a (Fig. 3b). The bromine
is held by van der Waals and weak electrostatic interac-
tions ranging from 3.5 to 3.8 Å with the main chain of
Gly149 and Gly150. Interestingly, the loop 230–236 from
a neighboring dimer, specifically the main chain atoms of
Phe232″ and Glu233″, forms the majority of interactions
with the other naphthoquinone ring, which contains a
hydroxyl group in place of the bromine. Van der Waals
interactions with Gln66′, Ala67′, Pro68′ and Val 72′ also
help hold this ring in position. To verify this positioning
of the second naphthoquinone ring is not an artifact of
crystal packing, we co-crystallized hNQO1 with E6a.
These crystals show poor diffraction to 3.5 Å and belong
to the space group P41212. This crystal form has a differ-
ent packing where we do not see the loop 230–236 of the
neighboring molecules interacting with the active site
(data not shown). This crystal form also shows a similar
binding mode for E6a, confirming that binding mode and
orientations of the two naphthoquinone rings are unique
and independent of the crystal form. Movement of the
main chain of loop 230–236 and side chain of Phe232 is to
accommodate the substrates and is mentioned in previ-
ously reported structures of NQO1 complexed with dicou-
marol (2F1O), duroquinone (1QRD) and ES936 (1KBQ)
[28, 29, 31]. It was also shown that a specific conformation
of Tyr128′ and Phe232′ is important for NQO1 inter-
action with p53 and the movement in these residues upon
the binding to dicoumarol changes the surface properties
of hNQO1, rendering it incapable of binding to its client
proteins like p53 and p73β [11].
Increase in FAD fluorescence upon E6a binding
FAD, the co-factor of hNQO1, is naturally fluorescent.
Fluorescence of FAD bound to several proteins like fla-
vodoxin, lactate oxidase, etc. in its oxidized state exhibits
much higher fluorescence intensity than that of its
reduced state [32, 33]. In the case of cholesterol oxidase,
on and off states of FAD fluorescence were observed as
the redox state of flavin toggles between oxidized (FAD)
and reduced states (FADH2) [34]. Interestingly, the
fluorescence of FAD bound to hNQO1 [61.1 +/− 1. 7
relative fluorescence Units (RFU) (n = 3)] showed a 5-
fold increase [306.3 +/− 12.1 RFU (n = 3)], upon E6a
binding (Fig. 4). Fluorescence of E6a alone at an excita-
tion of 425 nm and emission of 525 nm was negligible.
This increase in FAD fluorescence could be attributed to
the oxidation of hNQO1-FADH2 to hNQO1-FAD upon
E6a binding, which in turn results in conversion of E6a
to its hydronaphthoquinone counterpart. The reduced
form of E6a, i.e. hydronaphthoquinone, can quickly cycle
back to oxidized form of E6a by generating ROS includ-
ing superoxide and peroxide. As a positive control, we
observed an increase in fluorescence of FAD bound to
hNQO1 in presence of hydrogen peroxide (H2O2) to
284.2 +/− 8.6 RFU (n = 3). The fluorescence of FAD and
E6a in the absence of protein is very low [12.52 +/− 0.1
RFU (n = 3)]. These results confirm that oxidation of
FAD by E6a occurs only in the context of the hNQO1-
FAD complex. Our previous results showed that in yeast,
dimeric naphthoquinones generate ROS in a concentra-
tion dependent manner [9]. The FAD fluorescence
results are consistent with our previous prediction that
dimeric naphthoquinones engage hNQO1 in futile redox
cycling and generation of ROS.
Comparison of E6a binding to that of other quinone-based
chemotherapeutic agents
E6a binds in the same active site pocket as that of the
chemotherapeutic quinones but in a different orientation
(Fig. 5). The brominated naphthoquinone ring occupies
Fig. 4 Increase in hNQO1+FAD fluorescence upon E6a binding. The
relative fluorescence units (RFU) of each sample were measured in
triplicate and the standard deviations are represented as error bars.
Unpaired t-test analysis of hNQO1+FAD+E6a versus hNQO1+FAD+H2O2
resulted in a p value of 0.212 while all other combinations gave p values
less than 0.001
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a similar position and orientation as that of the aromatic
core of the chemotherapeutic quinones RH1 (PDB Code:
1H66, Additional file 4: Figure S4) and ARH019 (PDB
Code: 1H69, Additional file 4: Figure S4) (Fig. 5b, f ), but
shifted by 1.4 and 1.9 Å, with respect to RH1 and
ARH019, respectively, towards the central ring of the fla-
vin and away from His161 and Phe178′. In this position,
the benzene ring of the brominated naphthoquinone
ring has interactions with Trp105 and Tyr126′ similar to
those of the aziridinyl group of RH1 and ARH019. In
contrast to RH1 and ARH019, the quinone oxygen O19
of E6a is hydrogen bonded to Tyr126′ but not to
Tyr128′. Instead, the quinone oxygen O20 of E6a is
hydrogen bonded to Tyr128′, the side chain of which
occupies a different position when compared to the
structures of other quinone-based chemotherapeutics
(Fig. 5a, c, e). In this position, oxygen O20 of E6a is 4.5 Å
from His161, a residue that forms a hydrogen bonding
interaction with RH1, ARH019, and E09 (discussed
below). The other naphthoquinone ring of E6a is posi-
tioned in a different pocket lined by main chain of Gln66-
Pro68 when compared to the 2-phenyl group of ARH019
stacking with Gly149 and Gly150. The bromine of E6a
interacts with Gly149 and Gly150. In contrast to the other
quinones, the quinone ring of E09 (PDB Code: 1GG5,
Additional file 4: Figure S4) aligns with the naphthyl ring
of E6a and the indole ring of E09 aligns with the
brominated quinone ring of E6a (Fig. 5d). This shift rela-
tive to E6a appears to be facilitated in part by favorable
van der Waals interactions created with the side chains of
residues Phe178, Phe106′, and Trp105′ and the aziridinyl
ring of E09. In addition, hydrogen bonds from His161′
and Tyr126 to the quinone oxygen of E09 appear to
stabilize this orientation. In the E6a structure, only the
van der Waals contacts between Phe178 and the naphthyl
ring of E6a are maintained relative to the E09 structure.
The main differences in the active site residues include
the orientation differences in the side chains of His161,
Tyr126′, Tyr128′ and Phe178′. Tyr128′ shows a large
swing in its side chain away from the active site to
accommodate the second naphthoquinone ring. The
loop 230–236 from a neighboring dimer interacting
with E6a bound in the active site could also contribute to
this position of Tyr128′. These structures of chemothera-
peutic quinones clearly show that these compounds, even
the ones with highly similar pharmacophores, can “float”
along the isoalloxazine ring of FAD and bind to the en-
zyme in different orientations as dictated by interactions
with side chains in the active site [30]. The smaller size of
these compounds when compared to the active site pocket
gives them flexibility to migrate to positions best suited
for their substitutions at various positions. This property
might make optimization and/or rational design quite
difficult because chemical modification of the compounds
Fig. 5 Comparison of the mode of binding of E6a to that of other chemotherapeutic quinones. Residues from the hNQO1-E6a complex are shown in
blue and E6a is shown in green. Residues from the quinone complex structures are shown in orange (ARH019), pink (E09), and brown (RH1). a, c and e
depict the conformational changes in the active site residues while (b), (d) and (f) show variations of binding modes of E6a and quinone-based
chemotherapeutic agents ARH019 (orange), E09 (pink) and RH1 (brown), respectively
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could change their binding orientation, thereby thwarting
the intention of the design. On the other hand, the
dimeric naphthoquinones are bulky, occupy most of the
active site, and appear to have little room for changing
orientations. This opens up the possibility for a design in
which the halogenated naphthoquinone ring is anchored
at the FAD and the other naphthoquinone ring can be
optimized to improve efficacy.
Comparison of E6a binding to coumarin-based inhibitors
of NQO1
In contrast to the other therapeutic quinones, the position
and orientation of bound E6a differs markedly when
compared to those of coumarin-based inhibitors of NQO1
including dicoumarol (PDB Code: 2F1O) and AS1 (PDB
Code: 3JSX, Additional file 4: Figure S4) (Fig. 6). The
coumarin ring of dicoumarol that stacks against the isoal-
lozaxine ring of FAD is stabilized by the hydrogen bonds
between O5 and Tyr128′ and O17 and NE2 of His161.
The other coumarin ring is stacked against Tryr128′ and
is held in position by hydrogen bonds between O38-
His161 and O32-Gly149 main chain. The crystal structure
of hNQO1-AS1 complex shows that the coumarin ring of
AS1 that stacks against the flavin ring binds in the
same position but in a different orientation to that of
dicoumarol (Fig. 6b), with its hydroxyl group at position 4
interacting with Tyr128′ while O2 and O7 are hydrogen
bonded to His161 (Fig. 6a). This is clearly due to the me-
thyl substitutions at positions C1 and C6 of this coumarin
ring. The naphthyl group of AS1 occupies similar position
to that of the second coumarin ring of dicoumarol but in
a perpendicular direction interacting mainly with Gly149,
Gly150, Met154, Phe232′ and Tyr128′ (Fig. 6d). In this
crystal structure, the naphthyl ring interacts with Phe232″
and Glu233″ of the neighboring dimers due to crystal
packing, with the distances ranging from 3.5 to 5.8 Å in
eight monomers present in the asymmetric unit. The
overall binding pocket but not orientation of the bromi-
nated naphthoquinone ring of E6a matches that of the
coumarin ring of dicoumarol and AS1 that stacks against
the flavin, mirroring the van der Waals interactions with
Tyr126′, Phe178 and Phe106. However the hydrogen
bonding pattern differs in the case of E6a. The striking
difference in E6a binding compared to that of the
coumarin-based derivatives is the positioning of the
second naphthoquinone ring in a pocket lined by the main
chains of Gln66-Pro68, phosphates of FAD. In the second
ring of dicoumarol and AS1, both occupy a different
pocket which resides 8.0 Å away from the pocket occupied
by the corresponding ring on E6a. Other differences in the
active site include the conformation of side chains of
His161, Phe106, His 194, Tyr128′ and Phe232′ (Fig. 6a, c).
Fig. 6 Comparison of E6a and coumarin-based NQO1 inhibitors binding to the active site of hNQO1. Residues from the hNQO1-E6a complex are
shown in blue and E6a is shown in green. Residues from the coumarin complexes are shown in gray (dicoumarol) and brown (AS1). a and c show
the structural differences in the active site residues of hNQO1-dicoumarol and hNQO1-AS1 with reference to the hNQO1-E6a complex. b and d
show the differences in binding orientations of dicoumarol (gray) and AS1 (brown) compared to that of E6a
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The mechanism of dicoumarol inhibition involved increas-
ing superoxide levels via inhibition of NQO1 [35–37].
However, other coumarin-based inhibitors show minimal
or no superoxide generation though they show efficient in-
hibition of hNQO1. Dimeric naphthoquinones on the
other hand showed a concentration dependent ROS gener-
ation in yeast [9]. Our earlier studies on MDA-453 and
PC-3 cancer cell lines suggested that generation of reactive
oxygen species leading to oxidative stress and mitochon-
drial dysfunction are the anti-cancer mechanisms of this
class of compounds [6, 7].
Conclusions
The crystal structure of hNQO1 complexed with FAD
and E6a presented here is the first evidence of direct
interaction of the dimeric naphthoquinones with NQO1
at the active site. This is a valuable starting point for
better understanding of the mode of binding of dimeric
naphthoquinones to NQO1. Such data are required in
order to establish structure activity relationships that
support further structure-based optimization to improve
the anti-neoplastic efficacy of this novel class of chemo-
therapeutics. High resolution crystal structures of hNQO1
with more dimeric naphthoquinones would help to under-




DNA for hNQO1 was codon optimized for expression in
Escherichia coli and subcloned into a modified pET19b
vector containing N-terminal 10XHis tag and PreScis-
sion protease cleavage site preceding the insert. The ex-
pression plasmid was transformed into BL21 (DE3) cells.
Cells were grown at 37 °C to an OD600 of 0.6 and in-
duced with 0.3 mM Isopropyl β-D-1-thiogalactopyrano-
side (IPTG) at 18 °C overnight. The cells were harvested
at 4000 rpm for 20 min and resuspended in lysis buffer
containing, 50 mM Tris pH 8.0, 500 mM NaCl and
2 mM beta-mercaptoethanol. The cells were lysed by
sonication and soluble proteins were separated by centri-
fugation at 15000 rpm for 45 min. The clarified lysate
was first purified using Ni-affinity chromatography. The
histidine tag was removed from the purified hNQO1 by
preScission protease cleavage, combined with a dialysis
against 50 mM Tris pH 8.0, 150 mM NaCl and 1 mM
DTT. Cleaved hNQO1 was further subjected to a final
purification step using size exclusion chromatography.
Crystallization and structure determination
hNQO1 stored at a concentration of approximately
18–20 mg/ml in 50 mM Tris pH 8.0, 50 mM NaCl and
5 μM FAD was used for crystallization screening. Initial
screening with JCSG+, Classics suite I and II from Qiagen
resulted in initial hits in more than 20 conditions. Native
data up to 2.0 Å resolution were collected using P21 crys-
tals obtained in 20 % (w/v) PEG3350 and 0.2 M Ammo-
nium Citrate. Another crystal form in the space group
P212121 were obtained using 20 % PEG3350 and 0.2 M
Potassium Sodium Tartarate. The complex between
NQO1 and E6a was obtained by soaking the P212121 na-
tive crystals in mother liquor containing 1 mM E6a. X-ray
diffraction data were collected in house and at beam line
5.0.3 of the Advanced Light source at Lawrence Berkeley
National Laboratory for the holo and E6a-bound hNQO1
crystals respectively. The data were reduced using
iMosflm [38] and Aimless [39] from the CCP4 program
suite. Initial phases for both holo and E6a-bound hNQO1
were determined by molecular replacement using the pro-
gram Phaser [40–43] using the coordinates of an hNQO1
monomer from a previously reported holo-structure (PDB
accession code: 1D4A) [26]. The initial molecular replace-
ment solution for the hNQO1-E6a complex contained
only 8 of the 14 monomers in the asymmetric unit. Using
these 8 monomers as a fixed solution, the remaining
monomers were placed iteratively using a combination of
Phaser [40–43] and Molrep [44]. The structure was
refined using Refmac5 [45–49] from CCP4 program
suite. Iterative cycles of model building using COOT
[50–53] and refinement by refmac5 and TLS- and
NCS- restrained [54] refinement using buster [55]
yielded final structures with Rwork/Rfree of 18.0/21.6
for native and 18.3/22.0 for the E6a complex. Final
Structures were deposited in PDB (Accession Codes:
holo–hNQO1: 5EA2, hNQO1-E6a: 5EAI).
Fluorescence measurements
All fluorescence measurements were done using Spectra-
Max M5 plate reader at room temperature. An absorbance
scan for 100 μM FAD in 50 mM Tris pH 8.0 and 50 mM
NaCl resulted in a peak at 440 nm. The excitation wave-
length was chosen to be 425 nm for FAD to avoid overlap
of excitation and emission peaks. An emission scan with an
excitation wavelength at 425 nm resulted in a peak at
525 nm. These wavelengths were confirmed by performing
similar scans with FAD bound to hNQO1 in the same buf-
fer and thus were used for all of the fluorescence experi-
ments. Approximately 100 μl of each of the following
samples in 50 mM Tris pH 8.0, 50 mM NaCl and 5 μM
FAD were added in the wells of a costar Black/clear bottom
96 well plate. Fluorescence of hNQO1 alone in the above
buffer was initially recorded. Next, NQO1 supplemented
with 1 mM E6a in the above buffer was analyzed. A
mixture of 5 μM FAD and 1 mM E6a mixture in the above
buffer was used as a negative control. Approximately
100 μM hydrogen peroxide was added to the NQO1
sample and used as a positive control for the oxidized FAD.
These data were analyzed using softMax Pro software.
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Availability of supporting data
The atomic coordinates and structure factor amplitudes
are available in the Protein Data Bank repository (PDB),
Accession Codes 5ea2 (holo-NQO1) and 5eai (NQO1-E6a
complex).
Additional files
Additional file 1: Figure S1. The chemical structure of E6a (3-bromo-3′-
hydroxy-2,2′-binaphthalenyl-1,4,1′,4′-tetraone). (PNG 40 kb)
Additional file 2: Figure S2. Superposition of active site residues in
holo-hNQO1 structures from the current study (Cyan) and previously
reported structure 1D4A (gray). (PNG 1167 kb)
Additional file 3: Figure S3. Two dimers of E6a bound hNQO1 structure
showing the loop 230–236 interacting with the active site of neighboring
dimer. The FAD molecules are shown in stick representation in each active
site. The E6a molecule is shown in ball-and-stick representation. (PNG 2799 kb)
Additional file 4: Figure S4. The chemical structures of other known
inhibitors of NQO1. (PNG 79 kb)
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